Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Palm Beach Research Center

Neither a doctor nor a teaching hospital

Research payments

$5,859,312

428 payments

Through program year 2025, Palm Beach Research Center is reported as receiving $5,859,312 in research payments, across 428 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $289,118 40
2024 Research $520,678 25
2023 Research $1,092,435 61
2022 Research $1,533,016 73
2021 Research $617,655 53
2020 Research $489,761 64
2019 Research $1,316,649 112

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,437,747 4 payments
  2. Eli Lilly and Company $1,039,864 40 payments
  3. Novartis Pharmaceuticals Corporation $863,329 2 payments
  4. Merck Sharp & Dohme Corporation $600,208 9 payments
  5. Ironwood Pharmaceuticals, Inc $459,525 86 payments
  6. Moderna TX, Inc. $365,179 26 payments
  7. GlaxoSmithKline, LLC. $277,368 70 payments
  8. AstraZeneca UK Limited $229,708 4 payments
  9. Emergent BioSolutions Inc. $195,876 53 payments
  10. Allergan Inc. $119,977 35 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $1,523,801 4 payments
  2. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $863,329 2 payments
  3. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $592,768 6 payments
  4. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $574,170 4 payments
  5. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $343,683 7 payments
  6. C3718-301 $311,322 53 payments
  7. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $183,189 51 payments
  8. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $142,020 22 payments
  9. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $120,562 2 payments
  10. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $119,977 35 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record